B-cell-specific plasma-membrane proteins are potential targets for either small molecule or antibody-based therapies. We have sought to annotate proteins expressed at the cell surface membrane in patients with chronic lymphocytic leukemia (CLL) using plasma-membrane-based proteomic analysis to identify previously uncharacterized and potentially B-cell-specific proteins. Proteins from plasma-membrane fractions were separated on one-dimensional gels and trypsinized fractions subjected to high-throughput MALDI-TOF mass spectrometry. Using this method, many known B-cell surface antigens were detected, but also known proteins not previously described in this disease or in this cellular compartment, including cell surface receptors, membrane-associated enzymes and secreted proteins, and completely unknown proteins. To validate the method, we show that BLK, a B-cell-specific kinase, is located in the CLL-plasma-membrane fraction. We also describe two novel proteins (MIG2B and B-cell novel protein #1, BCNP1), which are expressed preferentially in B cells. MIG2B is in a highly conserved and defined gene family containing two plasma-membrane-binding ezrin/radixin/moesin domains and a pleckstrin homology domain; the Caenorhabditis elegans homolog (UNC-112) is a membrane-associated protein that colocalizes with integrin at cell-matrix adhesion complexes. BCNP1 is a completely unknown protein with three predicted transmembrane domains, with three alternatively spliced final exons. Proteomic analysis may thus define new potential therapeutic targets.
Introduction
Chronic lymphocytic leukemia (CLL) is the commonest form of leukemia in North America and Europe accounting for 25% of all leukemias.
1 CLL remains incurable with the currently available chemotherapy, but the prognosis of these patients varies substantially. Some patients will require little or no therapy for many years, while others die rapidly with chemotherapy-resistant disease. The prognosis for fludarabineresistant disease is particularly dismal with most patients dying within 1 year. Monoclonal antibodies (MAbs), such as the CD52 MAb CAMPATH-1H, may be useful in some patients with hematological disease, but there remains an urgent need for new therapeutic approaches. 2 More recently, the application of genomic-scale gene expression profiling techniques has allowed the identification of a characteristic CLL gene profile, which is distinct from other subtypes of B-cell malignancy. [3] [4] [5] [6] This signature is seen in patients both with and without mutations in the IGHV gene segments, indicating that both subsets might arise from the transformation of the same cell type via similar methods of transformation. The genes within the CLL signature included many genes not previously thought expressed in CLL. These genes included WNT3, titin and ROR1 receptor tyrosine kinase. Proteomics provides information complementary to gene expression profiling, allowing the annotation of the protein content of cells, usually through two-dimensional (2D) gels and high-throughput analysis. Furthermore, individual subcellular fractions can be used in conjunction with this approach in order to study the protein content within a given cellular compartment. Hemopoietic malignancies provide an ideal situation to assess proteomic technology since pure tumor cells can be readily obtained. Studies on myeloid cell lines have shown that there may be significant differences between results obtained with gene expression profiling and proteomic analysis. This is not unexpected for the following reasons: the half-lives of proteins and their coding RNAs can be drastically different; and proteins exist in many different isoforms (caused by a range of post-translational mechanisms) than do alternatively spliced RNAs such that isoform specificity of a protein is controlled by modifying enzymes and not the coding RNA. Preliminary studies using 2D gels in CLL showed a correlation of largescale protein expression profiles with clinical data; patients with shorter survival times exhibited increased levels of heat-shock protein 27 and decreased levels of thioredoxin peroxidase 2 or protein disulfide isomerase, which may be associated with altered drug resistance. review and after obtaining informed written consent. RNA samples from patients with lymphoma were derived from pathologically validated clinical lymphoma tissues and obtained with full Institutional Review Board approval from Ardais Corporation (Lexington, MA, USA). The samples comprised 18 cases of diffuse large B-cell lymphoma (DLBCL), five cases of follicular lymphoma (FCL) and six cases of nodular sclerosing Hodgkin's lymphoma (HL). These RNA samples were derived from unfractionated biopsies and thus contained RNA derived from residual normal and reactive cells. Other RNA samples were purchased from Clontech (Palo Alto, CA, USA). Cell line RNA samples used in this study were derived from Raji, Daudi, (A46, Namolwa, Ramos, Mutu111, kHM10B and BL58 (Burkitt's lymphoma cell lines), OZ, SUDHL6 (DLBCL cell lines), Jurkat (T-cell ALL cell line), THP-1 and HL60 (AML cell lines) and COLO 775 (CML cell line).
Isolation of purified CLL cells
Patients with lymphocyte counts greater than 50 Â 10 6 /ml were selected for this study in order to minimize possible contamination of tumor cells by normal hemopoietic cells. Blood samples were collected into lithium heparin, diluted in an equal volume of phosphate-buffered saline (PBS) and then separated on FicollIsopaque medium. Mononuclear cells were collected from the interphase and washed in PBS and then incubated with magnetic microbeads coated with CD3 and CD14 (Miltenyi Biotec, UK); magnetically labeled cells were passed over a magnetic column to deplete residual T cells and monocytes specifically. The resulting CLL cells had a purity of 495% as determined by flow cytometry.
CLL-plasma-membrane isolation
Purified CLL cells (10 9 ) were washed in PBS three times. The cell pellet was resuspended in homogenization buffer containing 250 mM sucrose, 10 mM HEPES, 1 mM EDTA, 1 mM vanadate, 0.02% azide and protease inhibitors (Roche, Switzerland). Cells were fractionated using a ball bearing homogenizer (8.002 mm ball, HGM Lab equipment, EMBL, Germany) until approximately 95% of cells were disrupted. Membranes were fractionated using the method described by Pasquali et al. 8 The fractionated cells were centrifuged at 3000g for 10 min at 41C and the post-nuclear supernatant was layered onto a 60% sucrose cushion and centrifuged at 100 000g for 45 min. The membranes were collected and layered on a preformed 15-60% sucrose gradient and spun at 100 000g for 17 h. Proteins from the fractionated sucrose gradient were run on a 4-20% 1D gel (Invitrogen, UK) and subject to Western blotting. Those fractions containing CD20 , flotillin or transferrin immunoreactivity but not oxido-reductase II or calnexin immunoreactivity were pooled and represented the plasma-membrane fraction. For cytosolic fractionation, CLL cells were resuspended in 5 ml of homogenization buffer and sonicated on ice. The cells were centrifuged at 1000g for 5 min and the supernatant was spun at 100 000g for 60 min at 41C. The soluble fraction represented the cytosol fraction, and the pellet the membrane fraction.
1D gels, proteolysis and MALDI-TOF MS
Plasma-membrane fractions from the same CLL samples were run in adjacent lanes on the same 1D gels and sequential 0.5 mm gel slices were excised from the 1D gels between 250 and 20 kDa. The molecular weight of each gel slice was recorded and then each slice subjected to trypsin digestion. The resulting peptide fragments were analyzed by MALDI-TOF-MS (Voyager STR, Applied Biosystems, Framingham, MA, USA) using a 337 nm wavelength laser for desorption and the reflectron mode of analysis. Selected masses were further characterized by tandem MS using a QTOF-MS equipped with a nanospray ion source, (Micromass UK Ltd, Manchester, UK). Prior to MALDI analysis, the samples were desalted and concentrated using C18 Zip Tipst (Millipore, Bedford, MA, USA). Samples for tandem MS were purified using a nano-LC system (LC Packings, Amsterdam, The Netherlands) incorporating C18 SPE material. Using the SEQUEST search program, 9 uninterpreted tandem mass spectra of tryptic digest peptides were searched against a database of public domain proteins constructed of protein entries in the nonredundant NCBI database (http://www.ncbi.nlm.nih.gov/) and Swissprot (http:// www.expasy.com). Peptide matches identified by SEQUEST were filtered according to their crosscorrelation score (Xcorr), normalized difference correlation score (DC n ), compatibility with trypsin digestion, and number of observations of proteins and peptides. Peptides were only used for protein identification where XcorrX1.2 and DC n X0.2. For conservative identification of abundant proteins two peptides with these scores were required, but for some of the novel lower abundance proteins identified we accepted a single tandem peptide with these scores so long as there were mass matches on the same protein sequence from the same gel slice. Thus, a virtual 1D molecular weight protein map was created, which also enabled comparisons of the molecular weight of proteins positively identified by tandem mass spectra in samples.
Western blotting
Western blots were performed as previously described. 10 Cell extract or membrane protein (10 mg) were run on a 4 -20% 1D gel and transferred to PVDF membrane (Invitrogen). Membranes were blocked with 3% milk powder (Marvel), incubated with anti-BLK (Santa Cruz, 329), and then incubated with anti-rabbit HRP (Amersham). Immunoreactive bands were developed using the ECL detection system (Amersham).
Quantitative RT-PCR
Real-time RT-PCR was used to quantitatively measure MIG2B and BCNP-1 expression in normal human tissue mRNAs (Clontech), cell lines (American Type Culture Collection), and CLL and B-NHL samples. The primer pairs used traversed introns and test products were sequenced to confirm specificity before use in these assays. PCR products from all samples were analyzed on agarose gels and positives shown to contain a single PCR product of the size predicted from cDNA. No fragments of the size predicted from genomic DNA were detected in any samples demonstrating the complete absence of genomic DNA contamination. All reactions were run twice and any samples showing a 410% variation in copy number excluded from analysis. The primers used for PCR were as follows:
B-cell novel protein #1 (BCNP1): sense 5 0 GGTGGTCGTG-GGGAAGGGAAGA3 0 (exon 1) and antisense: 5 0 CCACGGTA-GCAAGGCAGGAAGT3 PCR reactions containing 5 ng cDNA, SYBR green sequence detection reagents (PE Biosystems), Taq polymerase, sense and antisense primers were assayed on an ABI7700 sequence detection system (PE Biosystems). The PCR conditions were one cycle at 501C for 2 min, one cycle at 951C for 10 min, and 40 cycles of 951C for 15 s, 651C for 1 min. The accumulation of PCR product was measured in real time as the increase in SYBR green fluorescence, and the data were analyzed using the Sequence Detector Program v1.6.3 (PE Biosystems). Standard curves relating initial template copy number to fluorescence and amplification cycle were generated using the amplified PCR product as a template, and were used to calculate copy number in each sample.
Results

Protein identification
CLL-plasma-membrane protein fractions were resolved on a 1D SDS-polyacrylamide gel and sequential 0.5 mm gel slices containing proteins subjected to exhaustive trypsinolysis. The resulting tryptic peptides were analyzed by MALDI-TOF MS. Sets of peptide masses thus obtained from each gel slice were compared to theoretical tryptic masses of known primate protein sequences (GenBank PRI division http://www.ncbi.nlm.nih.gov) using the MOWSE algorithm. 11 Three successive rounds of mass matching were carried out for the peptides from each gel slice and peptide masses were arranged into three clusters representing the protein sequence with the highest number of matches for each round. This process enabled selection of peptides for subsequent QTOF tandem mass spectrometric analysis to be biased away from those found in proteins most frequently identified by MS, 12 such as structural, heat-shock and MHC proteins. In all, 500 proteins were identified by mass-and fragment-based searching of the public databases. A total of 365 (74%) of these were previously characterized proteins of known subcellular localization; the other 26% of proteins comprised both hypothetical proteins (15%) and proteins whose subcellular localization has not been determined (11%). Of the 365 previously characterized proteins, 238 (65%) were known membrane-associated proteins, while the remaining 35% were known non-membrane proteins, reflecting contamination of the membrane preparation with soluble cytosolic proteins.
Previously described CLL-associated cell surface proteins were identified in the derived plasma-membrane fractions. 13, 14 These included molecules utilized as diagnostic markers in CLL including CD5, CD19, CD20, CD22 and CD23, but also other B-cell-restricted molecules such as CD72. Many integrin-related molecules including CD11a/b/c, CD29, CD41, CD49d/e and ICAMs CD51 and CD53 were also detected in this fraction, as were CD73 and CD166 (data not shown). Although highly abundant, CD52 was not detected, presumably since this is a small peptide of 12 amino acids that generates on trypsinolysis few peptides of very low molecular weight that may not be visible with these methods.
15 Table 1 lists some of the uncharacterized proteins identified in this study that formed the basis of our efforts to describe novel B-cell-specific membrane proteins. The selection of BCNP1 and MIG2B for further investigation was based primarily on the paucity of expressed sequence tags (EST) data (the peptide identified for BCNP-1 only matched to genomic sequences at the time of discovery) or a hint of specificity in B cells from publicly available ESTs (MIG2B).
Novel findings from proteomic analysis of CLL membrane fractions
The combination of subcellular proteomics and genomics can also add significantly to the definition of genes currently defined only by ESTs, cDNA clones or theoretical transcripts predicted from raw genomic sequences by algorithms such as Genscan. 16 In all, 115 of the proteins we identified by MS analysis of CLL membranes had only previously been identified by the above methods. Given that 238 (65%) of the 365 previously characterized proteins we identified were known membrane proteins, and that 133 (56%) of these were in some way localized to the plasma membrane, it might be expected that up to 42 of the 115 uncharacterized proteins would therefore also be plasma membrane proteins. The known tissue distribution of encoding mRNAs (http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?db ¼ unigene), and/or homology to known proteins (http:// www.ncbi.nlm.nih.gov/BLAST), or the presence of predicted transmembrane domains (http://www.ch.embnet.org/software/ TMPRED_form.html), were assessed where possible for this set of proteins. Proteins with either restricted expression, or homology to protein families known to be involved in cancer or with predicted transmembrane domains were then subjected to mRNA profiling in a panel of primary CLL and lymphoma samples.
We discuss here the membrane specificity of the BLK kinase and the preliminary characterization of two of the novel proteins, MIG2B and BCNP1 (Table 1) .
Identification of BLK at CLL membrane BLK is a 55 kDa non-receptor tyrosine kinase of the SRC family of kinases that is expressed preferentially in B cells. The human gene is overall 87% identical to the murine, but has an NH2-terminal insertion of six amino acids, which was thought to indicate possible insertion into the plasma membrane. The function of BLK is poorly understood, but it may play an important role in the signaling pathways controlling cell proliferation and differentiation. 17 Its cellular localization in leukemic cells had not been determined. To confirm the results of the proteomic analysis, which suggested an association with the plasma membrane, we assessed the level of BLK immunoreactivity in purified CLL Full length BCNP1 (Isoform 1)
L C L L T Q P A W P S S * 2161 GGAGTGCATCTGAGCCACAGAGGGACCCTCTAAACCCAGGCTCTGACATGCATGTGAGCT 2220 2221 CAGCCCTGGGGGGCTGAGATTGTGGTGAATTTGTGTCCCATCTCT 2265
Alternatively spliced final exon 1 (Isoform 2)
GATGAGGAAACTGAGGCTGAGCGGGAAGGAGGGGCTTGTCCCAGGCAGCCAGACTCTGGT 60 D E E T E A E R E G G A C P R Q P D S G 6GCCCAGATCCAGCCACTCTGCCCACCGCCTTCTCCAGGAACATTCCGGAGCTGAATCTTC 120
A Q I Q P L C P P P S P G T F R S * 121 ACCCACATCTATCTTGTTTCTATTGGATAAATGTCTACAAGTGGAATTTCTGGGCCAAAA 180 181 CGGATGTGCCATCTTTAGGCTTTTGTAACCCCTGCAACTTCAGAAAACTGTACCATTTTA 240 241 TAAAAAAAAAAAAAAAAA 218
Alternatively spliced final exon 2 (Isoform 3)
L S H S L E T V S S H S V W S F R P T 241 CCAAGACAATGAGATATTCCTGNCCTTTCCNCCTATTTCCCTCCAACCCCNCCTTCCGAA 300
P R Q * 301 ATACATTTGCTCAATCATTTGCACTTCATAGGCCAAAAAAAAAAAAAAAAAAAAAAAAAA 360 Figure 2 DNA and protein sequence of BCNP1. There are three alternative final exons spliced at nucleotide 1981 (highlighted G) in the primary sequence and replaced by the sequences beneath. The three BCNP1 isoforms have been submitted to GenBank and their accession numbers are: isoform 1 AY254197, isoform 2 AY254198 and isoform 3 AY254199. membrane and cytosol fractions. Western blotting of CLL cytosol and membrane preparations with anti-BLK antibody revealed that BLK immunoreactivity was high in membrane preparations but barely detectable in cytosol preparations (Figure 1 ). This indicates that in CLL, BLK is localized almost exclusively to the cell-surface membranes. In support of this result, no BLK was detected in the cytosol fraction of the same CLL samples by tandem MS (data not shown).
Identification and cloning of BCNP1
Microsequencing of a peptide from a gel slice at approximately 80 kDa identified a GenScan predicted protein containing 21 exons (http://www.ensembl.org). Sequence database searching identified several public domain ESTs that showed strong homology to different regions of the predicted transcript. Alignment of the predicted protein with genomic DNA allowed the design of multiple PCR primers covering the putative openreading frame. These primers were then used to clone the entire gene from normal spleen and Daudi cell line cDNA preparations. We have termed this gene BCNP1. We identified three BCNP1 isoforms each with a different alternately spliced final exon encoding three proteins of 667, 652 and 698 amino acids (GenBank accessions AY254197, AY254198, AY254199 respectively) (Figure 2 ). The full-length BCNP1 sequences are predicted to contain three transmembrane domains and showed no significant homologies to known protein classes and contained no known protein motifs (Figure 2 ). The protein was however 31% identical to a gene of unknown function, NIBAN, which is upregulated in renal carcinoma. 18 All the matching ESTs on the public databases came from Bcell cDNA libraries, and thus BCNP1 was a clear candidate for more detailed examination as a potential new B-cell antigen. Quantitative RT-PCR analysis showed that BCNP1 was highly expressed in CLL and lymphoma samples and restricted to B-cell containing tissues (Figure 3) . Furthermore, there was far more BCNP1 mRNA expressed in B-cell malignancies than in normal B-cell containing tissues.
Identification and characterization of MIG2B
In a gel slice from CLL membranes cut from approximately 60 kDa, three tandem peptides were found that matched the conceptual translations of cDNA clones derived from normal thymus (clone #AK093719 ) and from a Burkitt's lymphoma cell line (clone #BC004347). The latter is a 2502 bp cDNA clone predicted to encode a 236 amino-acid protein with a molecular weight of 27 kDa. However, there are many alternative methionines available in the proposed 5 0 UTR before an inframe stop codon is found for this clone. The thymus cDNA has a conceptual translation of 663 amino acids. Supporting the presence of the larger predicted protein, two of these tandem MIG2 is a gene whose expression is upregulated by mitogens in fibroblasts. 19 Its functions remain unknown. The Caenorhabditis elegans homolog (UNC-112), which shows 59% homology to MIG2B at the protein level, is involved in integrin localization at the plasma membrane and the formation of cell-matrix adhesion structures. 20 Interestingly, UNC-112 also interacts with the homolog of integrin-linked kinase or ILK. 21 In view of the similarity between this protein and MIG2, we have named this protein MIG2B. MIG2B was 52% identical and 76% homologous to MIG2 at the protein level. MIG2B contained two ezrin/radixin/moesin (ERM) domains indicative of a cytoskeletal association, separated by a pleckstrin homology domain, commonly found in eukaryotic signaling proteins. There were no obvious transmembrane domains in the MIG2B sequence. Although this protein was identified in CLL-plasmamembrane fractions its further identification in cytosol fractions (data not shown) suggests that this protein is also intracellular in CLL.
The MIG2B Unigene cluster (Hs.180535) appeared to be chimeric, but showed a strong hemopoietic bias with 440% of clones deriving from this lineage including clones from T-and B-cell leukemic cell lines, spleen, tonsil and bone marrow tissues.
Quantitative RT-PCR analysis showed extremely specific hemopoietic expression as well as increased expression in Bcell malignancies (Figure 4c ). MIG2B unlike BCNP1 had a more widespread expression in non-B-cell hemopoietic cell types, such as HL60, THP1 and Jurkat cell lines. We have however only observed this protein in CLL samples and not in the many other cell types such as endothelial, neuronal and epithelial we have examined by the methods described here (data not shown).
Discussion
The aim of this study was to derive a preliminary 'map' of the cell-surface proteins expressed in CLL in order to identify new potential therapeutic targets. CLL provides relatively easy access to pure intact malignant cells. We describe an efficient and reproducible method for the generation of plasma membranes from these primary cells. Cell-surface antigens are generally of high molecular weight and hydrophobic, and 1D gels allow these types of proteins to both enter the gel and to be resolved. The inability of previous proteomics studies to identify these proteins lies partly in the inability of 2D gels to resolve proteins of this type. Use of the MOWSE algorithm to target masses for sequence data generation has also played a part in biasing protein identification towards sequences of specific biological significance, and greater coverage of lower abundance proteins such as those involved in transmembrane signal transduction.
This study identified known proteins and proteins not previously recognized to be resident in the CLL-plasma- Figure 4 Continued membrane fraction. Also, a number of previously unidentified, novel proteins were detected (Table 1) . BCNP1 and MIG2B represent the type of novel protein with probable plasma membrane localization that this approach is capable of discovering. We cannot assign plasma membrane localization for these proteins with complete certainty due to contamination of the CLL-plasma-membrane fraction with intracellular membrane proteins and cytosolic proteins; confirmation of this point will require the development of specific antibody reagents. Nevertheless, the presence of three predicted transmembrane domains in BCNP1 and plasma membrane-binding ERM domains in MIG2B, are consistent with these proteins being localized to membranes. BCNP1 is a B-cell-specific protein, whose expression is retained and often upregulated in B-cell malignancies. The biological basis for this variability of expression remains to be determined. Whether BCNP1 or any of the other novel proteins identified in this project (Table 1b ) play a role in the pathogenesis of CLL remains to be determined. The importance of integrating proteomic and genomic technologies at many different levels is highlighted with the definition of MIG2B. Initial proteomic findings can be rapidly profiled at the mRNA level in large numbers of normal and disease samples and the cellular localization can be confirmed through protein tagging technologies in relevant models. If protein detection reagents and samples are available: the abundance and localization of protein in normal and disease samples can also be determined. If protein reagents or samples are not available, genomic-based approaches together with information from proteomic expression databases in which the relative levels and localization of proteins in different tissues or cells are known helps decisions to be made on further studies.
The study shows that it is possible to use proteomics, in combination with genomic analysis, to identify novel membrane proteins in CLL that may have disease relevance. Changes in protein localization or modification in normal and disease cells may provide novel prognostic markers and even drug targets. Further analysis of plasma membrane fractions from patients with CLL will allow the recognition of other potential targets. The challenge for proteomics will be to identify and exploit such changes therapeutically.
